Conolidine’s analgesic effects stem from its interaction with non-opioid pain pathways. Contrary to opioids, which bind to µ-opioid receptors inside the central nervous process, conolidine modulates alternate molecular targets. A Science Improvements study identified that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, whi